Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure
SOS is a rare complication of stem cell transplantation and has significant morbidity and mortality. We present three cases of SOS and highlight underlying risk factors for its development, such as impaired clearance of alkylating agents (especially melphalan) in patients with renal failure and prol...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/5382852 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555113246359552 |
|---|---|
| author | Urvi A. Shah Sengottuvel Viswanathan Beamon Agarwal Aditi Shastri Ioannis Mantzaris Murali Janakiram Noah Kornblum Ira Braunschweig Amit Verma Yang Shi John Reinus Olga Derman |
| author_facet | Urvi A. Shah Sengottuvel Viswanathan Beamon Agarwal Aditi Shastri Ioannis Mantzaris Murali Janakiram Noah Kornblum Ira Braunschweig Amit Verma Yang Shi John Reinus Olga Derman |
| author_sort | Urvi A. Shah |
| collection | DOAJ |
| description | SOS is a rare complication of stem cell transplantation and has significant morbidity and mortality. We present three cases of SOS and highlight underlying risk factors for its development, such as impaired clearance of alkylating agents (especially melphalan) in patients with renal failure and prolonged infection. Although, melphalan and cyclophosphamide cause SOS less commonly than alkylating agents such as busulfan, physicians must use caution when administering these drugs to patients with underlying comorbidities such as renal failure that may increase the likelihood of development of SOS. This is due to unpredictable pharmacokinetics in patients with renal failure and therefore close drug monitoring is required. With the recent FDA approval of defibrotide in 2016, outcomes of SOS have improved and physician awareness is important for prompt diagnosis and treatment. |
| format | Article |
| id | doaj-art-73be8317410748d49f5fa14e9d3d2e4c |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-73be8317410748d49f5fa14e9d3d2e4c2025-02-03T05:49:36ZengWileyCase Reports in Oncological Medicine2090-67062090-67142018-01-01201810.1155/2018/53828525382852Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal FailureUrvi A. Shah0Sengottuvel Viswanathan1Beamon Agarwal2Aditi Shastri3Ioannis Mantzaris4Murali Janakiram5Noah Kornblum6Ira Braunschweig7Amit Verma8Yang Shi9John Reinus10Olga Derman11Department of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Pathology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Pathology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Medicine, Division of Hepatology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USASOS is a rare complication of stem cell transplantation and has significant morbidity and mortality. We present three cases of SOS and highlight underlying risk factors for its development, such as impaired clearance of alkylating agents (especially melphalan) in patients with renal failure and prolonged infection. Although, melphalan and cyclophosphamide cause SOS less commonly than alkylating agents such as busulfan, physicians must use caution when administering these drugs to patients with underlying comorbidities such as renal failure that may increase the likelihood of development of SOS. This is due to unpredictable pharmacokinetics in patients with renal failure and therefore close drug monitoring is required. With the recent FDA approval of defibrotide in 2016, outcomes of SOS have improved and physician awareness is important for prompt diagnosis and treatment.http://dx.doi.org/10.1155/2018/5382852 |
| spellingShingle | Urvi A. Shah Sengottuvel Viswanathan Beamon Agarwal Aditi Shastri Ioannis Mantzaris Murali Janakiram Noah Kornblum Ira Braunschweig Amit Verma Yang Shi John Reinus Olga Derman Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure Case Reports in Oncological Medicine |
| title | Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure |
| title_full | Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure |
| title_fullStr | Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure |
| title_full_unstemmed | Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure |
| title_short | Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure |
| title_sort | sinusoidal obstruction syndrome sos in multiple myeloma with renal failure |
| url | http://dx.doi.org/10.1155/2018/5382852 |
| work_keys_str_mv | AT urviashah sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT sengottuvelviswanathan sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT beamonagarwal sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT aditishastri sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT ioannismantzaris sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT muralijanakiram sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT noahkornblum sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT irabraunschweig sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT amitverma sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT yangshi sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT johnreinus sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure AT olgaderman sinusoidalobstructionsyndromesosinmultiplemyelomawithrenalfailure |